Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real-World Cohort Study

    January 2025 in “ Dermatologic Therapy ”
    Caiyu Wang, Xiaoyi Xing, S Wang, Yu Chen
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This real-world cohort study assessed the efficacy and safety of baricitinib in 47 Chinese patients with alopecia areata (AA), including alopecia totalis (AT) and alopecia universalis (AU). The study found that 78.7% of patients achieved significant hair regrowth, with a mean onset time of 6.04 weeks, and 34% experienced complete regrowth. Eyebrow and eyelash regrowth occurred in over 85% of patients. Baricitinib was well-tolerated, with mild side effects and no severe adverse events. Patients with a disease duration of 4 years or less showed greater improvement. The study suggests baricitinib as an effective treatment for AA, with higher response rates than previous trials, and emphasizes the importance of early intervention and long-term maintenance therapy. Limitations include the small sample size and retrospective design, indicating a need for further research.
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results